Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332779 | 0.90 | ALDH1A1 (0.68) | HTR1AALDH1A1KMT2A | |
| SCHEMBL13440314 | 0.89 | HRH3 (0.61) | KDM4EL3MBTL1HTR1AHDAC1HRH3 | |
| SCHEMBL10257007 | 0.89 | HTR1A (0.68) | KDM4EHTR1AALDH1A1KMT2A | |
| SCHEMBL13089690 | 0.88 | L3MBTL1 (0.54) | KDM4EL3MBTL1HTR1AHDAC1HDAC8 | |
| SCHEMBL13089319 | 0.88 | KDM4E (0.53) | KDM4EL3MBTL1HTR1AHDAC1HDAC8 | |
| SCHEMBL13443097 | 0.88 | HRH3 (0.60) | KDM4EL3MBTL1HTR1AHDAC1HDAC8 | |
| SCHEMBL11982948 | 0.87 | HRH2 (0.56) | KDM4EL3MBTL1HTR1AHDAC1HDAC8 | |
| SCHEMBL7389420 | 0.87 | HDAC1 (0.56) | KDM4EL3MBTL1HTR1AHDAC1HDAC8 | |
| SCHEMBL13089688 | 0.87 | HTR1A (0.54) | KDM4EL3MBTL1HTR1AHDAC1HDAC8 | |
| SCHEMBL28919774 | 0.84 | HRH3 (0.67) | KDM4EHTR1AALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099761-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | VILLAPHARMA RESEARCH S.L. (ES) | 2010-03-11 | — | — | US | disclosed |
| WO-2008068272-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063026-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | KDM4E 4303/4885L3MBTL1 4258/4885HTR1A 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.